By contrast, as DAAs are being used in patients with advanced fibrosis and cirrhosis, it was hypothesized that the risk of HCC in patients with DAAs-driven SVR would have been higher than that in patients with IFN-driven SVR. This evidence concerns the gene IFNA1 and Cirrhosis.